Compare DOMH & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | PRPO |
|---|---|---|
| Founded | 1967 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.2M | 32.4M |
| IPO Year | N/A | N/A |
| Metric | DOMH | PRPO |
|---|---|---|
| Price | $4.52 | $23.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 310.9K | 9.8K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | ★ 15.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 9.19 | N/A |
| Revenue | ★ $99,588,000.00 | $22,800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.47 | ★ N/A |
| Revenue Growth | ★ 691.07 | 30.95 |
| 52 Week Low | $0.83 | $3.90 |
| 52 Week High | $13.58 | $28.50 |
| Indicator | DOMH | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 49.57 | 53.04 |
| Support Level | $3.73 | $22.10 |
| Resistance Level | $4.70 | $25.03 |
| Average True Range (ATR) | 0.29 | 1.20 |
| MACD | 0.06 | -0.26 |
| Stochastic Oscillator | 58.67 | 50.76 |
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.